Buckeyes, I agree with your take that it is important to recognize the high risks of serious illness from covid infection in BoM2 study population. To me, being a non scientist, it makes sense to get moving on BoM2 and perhaps have covid outcomes as a secondary end point. It might even make enrolment easier if Docs can say that there is pre clincal evidence that Apabetalone may be beneficial to your personal outcome with covid if you are infected during the study. Covid infection with respect to the primary outcome would obviously have to be accounted for in any case, regardless of there being a covid secondary endpoint.